



# LEADING DIFFERENTLY TO WIN DIFFERENTLY

February 3, 2022

Sam Glick sam.glick@oliverwyman.com

A business of Marsh McLennan

# **CONFIDENTIALITY**


Our clients' industries are extremely competitive, and the maintenance of confidentiality with respect to our clients' plans and data is critical. Oliver Wyman rigorously applies internal confidentiality practices to protect the confidentiality of all client information.

Similarly, our industry is very competitive. We view our approaches and insights as proprietary and therefore look to our clients to protect our interests in our proposals, presentations, methodologies, and analytical techniques. Under no circumstances should this material be shared with any third party without the prior written consent of Oliver Wyman.

- 1 Truly understanding those we serve
- 2 Embracing that we're all now in the technology, pharmacy, and home businesses
- **3** Redefining the competition
- 4 Throwing out the old talent model
- Using M&A as a means, not an end
- 6 Not being tempted by false choices


# PRIMARY CARE IS DEAD! LONG LIVE PRIMARY CARE!

**PCP status**By Age



# WHEN YOU CARE ENOUGH NOT TO DO MUCH RESEARCH


**Source of the relationship with the doctor or primary care provider** By Age



# HELP ME. HELP ME HELP MYSELF. GET OUT OF MY WAY.

### Preferred method to decide about health and wellness


By Age and Gender



# **MANY "INFLUENCERS"**


### Sources of influence on decisions about the health

By Age. Percentage that responded "Highly Influential" or "Moderately Influential"



# MANY SOURCES OF KNOWLEDGE


**Endeavors to manage chronic health condition(s)**By Age



# **NOT EVERYONE'S "TRUTH" IS THE SAME**

### Do you agree with the following statement?

% that indicated they generally agree




Global data from US, UK, Brazil, Canada, France, Spain, Italy, Germany, Mexico. N = 8907 Source: Oliver Wyman Forum Global Consumer Sentiment Survey

- 1 Truly understanding those we serve
- 2 Embracing that we're all now in the technology, pharmacy, and home businesses
- **3** Redefining the competition
- 4 Throwing out the old talent model
- 5 Using M&A as a means, not an end
- 6 Not being tempted by false choices


# PHYSICAL OR DIGITAL? YES.

### Level of satisfaction with the selected front door vs. traditional care in a doctor's office



# **WANTED: MORE THAN JUST VIDEO VISITS**


### Level of importance of health innovations



## "WHY DO YOU ROB BANKS?"

Flow of a hypothetical \$100 expenditure on prescription drugs covered under private insurance through the US retail distribution system

Overall, combined average of both branded and generic



Source: USC Schaeffer Center for Health Policy and Economics © Oliver Wyman

# PHARMACY DISRUPTION IS UNDERWAY



# Legislative Action and Judicial Scrutiny

- 43 states have cost-disclosure laws;
   39 have passed anti-clawback laws
- Patient Right to Know Drug Prices Act
- Rutledge v. Pharmaceutical Care Management Association (PCMA)
- Prescription Drug Pricing Reduction Act of 2020
- Many others



# Attempts to take out waste in the manufacturing portion o the value chain

 Civica Rx is a nonprofit generic drug manufacturer founded in 2018 to reduce and prevent drug shortages in the United States and the price spikes that can accompany them



ENVISION R

Medimpact



# Smaller PBMs focused on transparent pricing, value prop customization and service

 Transparency is theoretically a differentiating factor, but it is not expanding as a business model



David Balto, attorney and former FTC Policy Director



A plethora of retail consumer offerings driving increased transparency and enhanced medication Care models









OD Medisafe








# Large out-of-industry incumbents entering the space in a big way

- Amazon launched its \$6-for-sixmonths deal on its Prime Day
- Walmart offered its Walmart+ subscribers access to prescription discount earlier on June 7



# New Partnerships to Create Disruptive Business Models


 Evio is startup funded by 5 BCBS plans that works with health plans to transform the medication experience for everyone: patients, providers, and the system at large



"Now that we've fallen in love, I have a confession. I'm not a giraffe—I'm fifty-eight weasels in a trenchcoat."

- Truly understanding those we serve
- Embracing that we're all now in the technology, pharmacy, and home businesses
- **3** Redefining the competition
- 4 Throwing out the old talent model
- Using M&A as a means, not an end
- 6 Not being tempted by false choices

# YOUR BIGGEST COMPETITOR IS TEN COMPANIES



**90%** of these companies will fail

**0%**of them want to be a hospital system

100%
of them want to take
1-10% share from you

Source: Oliver Wyman analysis

# THERE'S NOT ONE "BIG TECH"



- Start with transactional retail businesses where Amazon has a supply chain advantage (Rx, DME, etc.), then move into consumer health services
- Invest in AWS tailoring and targeted go-to-market for the healthcare vertical



- Focus on underlying technology to power providers in delivering care (AI, analytics, etc.)
- Continue to grow consumer healthcare advertising



- Focus on wellness and research, anchored by Apple devices
- Create an ecosystem of health app developers



- Target healthcare as a major enterprise growth vertical
- Strike strategic infrastructure partnerships with major healthcare players (Walgreens, Humana, Teladoc, etc.)




- Target healthcare as a major enterprise growth vertical
- Build targeted products for the healthcare vertical (e.g., care management platform built on CRM)

- Truly understanding those we serve
- 2 Embracing that we're all now in the technology, pharmacy, and home businesses
- **3** Redefining the competition
- 4 Throwing out the old talent model
- 5 Using M&A as a means, not an end
- 6 Not being tempted by false choices

# WE SHOULD HAVE SEEN THIS PROBLEM COMING

### **Annual Total Non-Farm Quit Rate**

2009-2021



Source: US Bureau of Labor Statistics

# **WE HAVE TO DO MORE THAN FIX BURNOUT AND PAY MORE**


"We should reframe the question- 'I don't work for Microsoft. Microsoft works for me'. Am I able to fulfill my career aspirations, my approach to having impact in the world? Somehow if Microsoft is acting as a platform for that, then it's very different. I feel connected with the mission."

- Truly understanding those we serve
- 2 Embracing that we're all now in the technology, pharmacy, and home businesses
- Redefining the competition
- 4 Throwing out the old talent model
- Using M&A as a means, not an end
- 6 Not being tempted by false choices

# Average Transaction Size for Hospital M&A

# FEWER, BIGGER HOSPITAL MERGERS

# Number and transaction size of announced hospital mergers 2009-2021



Source: Kaufman's 2020 M&A in Review; Q3 2021 Kaufman report

1 - 2021 only reflects Q1 - Q3 data

# **M&A FAILS FOR MANY REASONS**

Financial	Leadership distraction
	Unfulfilled growth and less focus on innovation and investment
Governance & Operational	Changes in operational or clinical models
	Incorrect and / or delayed integration decisions
	Potential data loss or other issues during the EMR integration
	Differences and inconsistencies in reporting and measurement methodology
Brand	Headline risks and impact on brand(s) driven by client, patient dissatisfaction, and talent attrition
	Turnover at all levels
Talent & Culture	Impact on employee engagement and morale driven by differences

- 1 Truly understanding those we serve
- 2 Embracing that we're all now in the technology, pharmacy, and home businesses
- Redefining the competition
- 4 Throwing out the old talent model
- 5 Using M&A as a means, not an end
- 6 Not being tempted by false choices

# **YES AND YES**

Physical	and	Digital
Episodic	and	Continuous
Evidence	and	Empathy
Clinical excellence	and	Operational excellence
Affordable	and	High-Quality
Build, Buy,	and	Partner
Cooperate	and	Compete
Mission	and	Margin

# **QUALIFICATIONS, ASSUMPTIONS, AND LIMITING CONDITIONS**

This report is for the exclusive use of the Oliver Wyman client named herein. This report is not intended for general circulation or publication, nor is it to be reproduced, quoted, or distributed for any purpose without the prior written permission of Oliver Wyman. There are no third-party beneficiaries with respect to this report, and Oliver Wyman does not accept any liability to any third party.

Information furnished by others, upon which all or portions of this report are based, is believed to be reliable but has not been independently verified, unless otherwise expressly indicated. Public information and industry and statistical data are from sources we deem to be reliable; however, we make no representation as to the accuracy or completeness of such information. The findings contained in this report may contain predictions based on current data and historical trends. Any such predictions are subject to inherent risks and uncertainties. Oliver Wyman accepts no responsibility for actual results or future events.

The opinions expressed in this report are valid only for the purpose stated herein and as of the date of this report. No obligation is assumed to revise this report to reflect changes, events, or conditions, which occur subsequent to the date hereof.

All decisions in connection with the implementation or use of advice or recommendations contained in this report are the sole responsibility of the client. This report does not represent investment advice nor does it provide an opinion regarding the fairness of any transaction to any and all parties. In addition, this report does not represent legal, medical, accounting, safety, or other specialized advice. For any such advice, Oliver Wyman recommends seeking and obtaining advice from a qualified professional.

